Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.1.1.67 (
thiopurine methyltransferase
)
551
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A meta-analysis was conducted to decide whether to reduce an initial 6-mercaptopurine (6-MP) dose in
TPMT
heterozygote in the case of an initial 6-MP dose of <75 mg/m
2
/d and to compare the tolerable 6-MP dose among different ethnic groups. The study was undertaken according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The differences in mean values of the tolerable 6-MP dose were calculated by using Comprehensive Meta-Analysis
version 3
. The results of the meta-analysis indicated that the tolerable 6-MP dose was significantly lower in the
TPMT
heterozygote group (difference in mean values =11.729, 95% confidence interval =7.617-15.842,
P
<0.001) even when the initial 6-MP dose was <75 mg/m
2
/d. The
TPMT*3C
allele-dominant ethnic group (Asian) needed less reduction in mean 6-MP dose in comparison to the
TPMT*3A
allele-dominant ethnic group (Caucasian, Mediterranean, South American) (difference in mean values =8.884 vs 15.324). In conclusion, the initial 6-MP dose needs to be reduced in
TPMT
heterozygote when compared to the wild-type, and ethnic difference might influence the tolerable 6-MP dose in
TPMT
heterozygotes.
...
PMID:Meta-analysis of the impact of thioprine
S
-methyltransferase polymorphisms on the tolerable 6-mercaptopurine dose considering initial dose and ethnic difference. 2792 May 53
